Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Molecular Devices  (Stock symbol: MDCC ) Acquired by MDS (2007 $ 615,000,000 )

1311 Orleans Drive
Sunnyvale, CA 94089
Website Company Summary Management Team

Outside board: (May no longer be on the board) Alan Finkel (Molecular Devices Former CEO) Moshe Alafi (Alafi Capital) David L. Anderson (Sutter Hill Ventures) A. Blaine Bowman (Dionex Former CEO) Andre Marion (Life Technologies Former CEO) Harden McConnell (Stanford University Professor) Allan Waitz (DNAX Research Former CEO)
Former outside board: Roy Whitfield (Incyte Former CEO) Paul Goddard (Neurex CEO);  Lev Leytes (LJL Biosystems)

Business description: Molecular Devices is a leading developer of high-performance, bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Our systems enable pharmaceutical and biotechnology companies to leverage advances in genomics and combinatorial chemistry by facilitating the rapid and cost effective identification and evaluation of drug candidates. Our instrument systems are based on our advanced core technologies which integrate our expertise in engineering, molecular and cell biology and chemistry. Our systems are fundamental tools for drug discovery and life science research, and our MAXline series of microplate readers and our FLIPR Cell Analysis systems are market share leaders in their respective markets.
Partners include: AbbottDionexDuPont;  NovelTech Systems

Capital raised: 18.0M
Ownership: Acquired by MDS (2007 $ 615,000,000 )
Stock Symbol: MDCC
Corporate investors: DionexLucent Venture Partners

Last Tweets


Last Mentions

Record updated: Jun 2014
Sector: Medical
Year Founded: 1983
Headcount: 301-400 as of May 2002
Capital Raised: 18.0M
Ownership: Acquired by MDS (2007 $ 615,000,000 )
Stock Symbol: MDCC